Overview

Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)